Skip to content. | Skip to navigation

Personal tools

This is SunRain Plone Theme

Navigation

banner4
banner14
banner1
banner8
banner9
banner5
banner3
banner2
banner12
banner7
banner16
banner18
banner0
banner10
banner13
banner11
banner17
banner15
banner6
You are here: Home / Events / Dott. David Monk: "Survival of human-specific germline methylation differences and the maintenance of allelic methylation"

Dott. David Monk: "Survival of human-specific germline methylation differences and the maintenance of allelic methylation"

Principal Investigator, Imprinting and Cancer Group, Cancer Epigenetic and Biology Programm (PEBC) IDIBELL Institut d'Investigació Biomèdica de Bellvitge Hospital Duran i Reynals 08908 L'Hospitalet de Llobregat (Barcelona) dmonk@idibell.cat
When Jun 17, 2019
from 12:00 PM to 01:30 PM
Where CNR Conference Room
Contact Name
Contact Phone +39 081 6132 444
Add event to calendar vCal
iCal

David Monk

2019- Lecturer, Biomedical Research Center (BMRC), School of Biological Sciences, Norwich, UK.

2008 – 2019:  Group Leader, Imprinting and Cancer Group, Cancer Epigenetics and Biology Program (PEBC), Bellvitge Institute for Biomedical Research (IDIBELL), Barcelona.

2006 – 2008:  Senior Post-doctoral Researcher: Institute of Child Health (ICH),

University College London (UCL), London, UK.

2004 – 2006:  Post-doctoral Researcher: IRDB, Imperial College London, London, UK.

2001 – 2004:  Multicenter Post-doctoral Researcher: MRC Harwell, Oxford, UK; The Babraham Institute, Cambridge, UK; IIRDB, Imperial College London, London, UK.

1998-2001:     PhD, Institute of Reproductive and Developmental Biology (IRDB), Imperial College London, London, UK.

The research interests of Dr Monks team are centered on understanding epigenetic mechanisms relevant to human diseases, focusing on the application of high-throughput genome technologies to analyze genomic imprinting. In particular, his studies have addressed the role of these epigenetically regulated transcripts in imprinting disorders, as well as fetal growth restriction, fertility and cancer. Recently, his group has utilized sequencing technologies to characterized methylation in human gametes and pre-implantation embryos, resulting in the identification of novel transient imprinted regions. In addition to his research activities, Dr Monk was involved in the European COST network for Human Congenital Imprinting Disorders (EUCID; 2015-2017), being the coordinator of the Molecular Biology working group. To date he has over 100 publications.

Filed under: